StockWatch
·

BLACK ROSE INDUSTRIES LTD.

BSE: 514183

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
91.25
+1.2%+8.2%
Expenditure
76.96
+1.3%-1.6%
Net Profit
10.49
+0.8%+136.7%
OPM %
13.81%
-2.34pp+5.22pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.0029.3458.6888.01117.35Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

Black Rose Industries: consolidated PAT +137% YoY on margin rebound, revenue up 4%

specialty chemicals · margin expansion · profit surge

ResultsQ2 FY2706 Nov 20263 minMetals & Mining

Black Rose Q1 FY27: consolidated PAT up 148% YoY as OPM expands to 16.2%

chemicals · acrylamide · margin expansion

ResultsQ1 FY2731 Jul 20263 minMetals & Mining
Latest
Board Meeting6 Nov, 2:47 pm

Black Rose Industries: consolidated PAT +137% YoY on margin rebound, revenue up 4%

Black Rose Industries' consolidated PAT for Q2 FY27 (quarter ended 30 September 2026) came in at ₹10.49 Cr, up 137% year-on-year from ₹4.43 Cr in Q2 FY26, while revenue from operations grew a much more modest 4.4% YoY to ₹87.68 Cr (₹83.98 Cr a year ago). Sequentially the print was flat — PAT up just 0.9% QoQ and revenue down 1.6% QoQ from Q1 FY27's ₹10.39 Cr PAT and ₹89.08 Cr revenue — so the YoY jump, not the QoQ number, is the real story this quarter; with revenue barely moving QoQ, the sequential comparison itself carries little signal beyond confirming the business has held its new, higher margin level. The entire YoY profit surge is a margin story rather than a volume story. Total expenses fell to 87.8% of revenue from 93.2% a year ago, lifting operating margin (OPM) to 13.8% from 8.6% YoY and net margin (NPM) to 11.5% from 5.3% YoY. Sequentially, margins eased slightly — OPM from 16.1% to 13.8% and NPM roughly flat at 11.5% vs 11.53% — as the expense ratio ticked up from 85.3% to 87.8% of revenue QoQ. EPS tracked the profit line: ₹2.06 this quarter versus ₹0.87 a year ago and ₹2.04 last quarter. No brokerage estimates for Black Rose could be found in a web search (public trackers show zero analysts covering the stock), so there is no street print to grade against; vsStreet is unknown. Against the company's own May 2026 concall guidance — subdued near-term distribution demand offset by higher pricing and a strong merchant-export pipeline, plus a positive manufacturing/acrylamide export outlook — this quarter's combination of muted topline growth with sharp margin recovery is broadly on-script, so the result reads as a guidance-met quarter rather than a beat or miss. No separate management press release accompanied this filing to cross-check against. At the same board meeting (6 November 2026) the company also approved Srishti Gour's appointment as Company Secretary and Compliance Officer; the VP Innovation's resignation in October and the routine SEBI KYC/insider-trading-window items from September are unrelated to the financial print. The consolidated accounts continue to carry B.R. Chemicals Co. (Japan) as discontinued operations pending its wind-up, a step the board further approved in July 2026 — its drag is now immaterial (a ₹0.0021 Cr loss this quarter) and should fully exit the consolidated book once the wind-up completes. Going into Q3, the key swing factors remain whether the acrylamide export pickup and merchant-export order pipeline flagged in management's prior commentary convert the current margin gain into faster revenue growth, and whether the long-flagged Specialty Amines project decision materialises.

6 Nov 2026, 02:47 pm

Corporate Events

Board MeetingBLACKROSE
2026
6Nov

Board Meeting

The Board of Directors will consider and approve Unaudited S…

BSE Filing ↗
Board MeetingBLACKROSE
2026
9Sep

Board Meeting

The Thirty Sixth (36th) Annual General Meeting will be held …

BSE Filing ↗
DividendBLACKROSE
2026
2Sep

₹1.25 / share

BSE Filing ↗
DividendBLACKROSE
2026
6Aug

₹2 / share

BSE Filing ↗
Board MeetingBLACKROSE
2026
31Jul

Board Meeting

The Board shall consider and approve the Un-Audited Standalo…

BSE Filing ↗
Board MeetingBLACKROSE
2024
5Nov

Board Meeting

Consider and approve the Unaudited Standalone and Consolidat…

BSE Filing ↗
DividendBLACKROSE
2024
9Aug

₹2 / share

BSE Filing ↗
Board MeetingBLACKROSE
2024
31Jan

Board Meeting

Consider and approve the unaudited standalone and consolidat…

BSE Filing ↗
Board MeetingBLACKROSE
2023
7Nov

Board Meeting

Consider and approve unaudited financial results

BSE Filing ↗
Board MeetingBLACKROSE
2023
8Aug

Board Meeting

Approval of unaudited standalone and consolidated financial …

BSE Filing ↗